3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
30
Carcinoma, Hepatocellular
13
Rectal Neoplasms
5
Sarcoma, Ewing
4
Osteosarcoma
4
Glioblastoma
4
Gastrointestinal Stromal Tumors
4
Colonic Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Esophageal Neoplasms
2
Chondrosarcoma
2
Bone Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Malignant Tumors
1
Small Cell Lung Carcinoma
1
Recurrence
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
regorafenib
×
1 year
×
Clear all
No trials found.